Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines PR Newswire - Thu Oct 19, 2023

/PRNewswire/ -- Flagship Pioneering today announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the...

DNLI : 15.56 (-3.41%)
FHTX : 5.21 (+0.97%)
MRNA : 108.85 (+0.89%)
OMGA : 2.33 (-0.43%)
SANA : 8.58 (+6.06%)
MCRB : 0.7295 (-4.01%)
Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics PR Newswire - Mon Oct 2, 2023

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFound™ Therapeutics, a company pioneering the discovery of a vastly expanded...

DNLI : 15.56 (-3.41%)
FHTX : 5.21 (+0.97%)
MRNA : 108.85 (+0.89%)
OMGA : 2.33 (-0.43%)
SANA : 8.58 (+6.06%)
MCRB : 0.7295 (-4.01%)
Flagship Pioneering Named to Fortune's 2023 "Change the World" List PR Newswire - Wed Sep 27, 2023

/PRNewswire/ -- Flagship Pioneering today announced it has been named to FORTUNE's 2023 "Change the World" list, an annual global ranking of companies that...

DNLI : 15.56 (-3.41%)
FHTX : 5.21 (+0.97%)
MRNA : 108.85 (+0.89%)
OMGA : 2.33 (-0.43%)
SANA : 8.58 (+6.06%)
MCRB : 0.7295 (-4.01%)
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer PR Newswire - Mon Sep 11, 2023

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business...

DNLI : 15.56 (-3.41%)
FHTX : 5.21 (+0.97%)
MRNA : 108.85 (+0.89%)
OMGA : 2.33 (-0.43%)
SANA : 8.58 (+6.06%)
MCRB : 0.7295 (-4.01%)
Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner PR Newswire - Tue Aug 29, 2023

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that pharma and healthcare leader David Khougazian is joining as...

DNLI : 15.56 (-3.41%)
FHTX : 5.21 (+0.97%)
MRNA : 108.85 (+0.89%)
OMGA : 2.33 (-0.43%)
SANA : 8.58 (+6.06%)
MCRB : 0.7295 (-4.01%)
Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines PR Newswire - Mon Aug 14, 2023

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Ampersand Biomedicines, a company programming smarter medicines that act...

DNLI : 15.56 (-3.41%)
FHTX : 5.21 (+0.97%)
MRNA : 108.85 (+0.89%)
OMGA : 2.33 (-0.43%)
SANA : 8.58 (+6.06%)
MCRB : 0.7295 (-4.01%)
Author
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential MarketBeat - Thu May 18, 2023

These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.

DNLI : 15.56 (-3.41%)
RARE : 44.28 (-1.84%)
SRPT : 124.25 (+6.09%)
PFE : 26.27 (-0.19%)
EXEL : 23.71 (+1.80%)
MRNA : 108.85 (+0.89%)
UTHR : 237.00 (+1.08%)
BIIB : 201.99 (+4.56%)
SNY : 46.61 (-2.26%)
LLY : 732.20 (-1.81%)
Why Shares of Denali Therapeutics Are Up Monday Motley Fool - Mon May 15, 2023

Analysts maintained their buy ratings on the clinical-stage biotech company.

DNLI : 15.56 (-3.41%)
Denali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus Zacks - Tue May 9, 2023

Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.

SNY : 46.61 (-2.26%)
BIIB : 201.99 (+4.56%)
LGND : 71.00 (+1.59%)
DNLI : 15.56 (-3.41%)
Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue Estimates Zacks - Mon May 8, 2023

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -12.68% and 15.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

DNLI : 15.56 (-3.41%)
SQZ : 0.4350 (+61.11%)

Barchart Exclusives

Is This Pullback Your Best Chance to Buy Nvidia Stock? Barchart - 10 minutes ago
As Nvidia experiences a pullback of approximately 18% from its recent highs, investors might be contemplating whether this presents an opportune moment to scoop up the stock. With concerns about valuation easing and analysts growing more bullish, this analysis explores whether now is the optimal time to consider investing in Nvidia. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot